Drug intelligence / Profile preview

Huizhisu (Beijing Anding Hospital)

Development stage: Unknown
Lead developer: Beijing Anding Hospital
Administration: Oral

Overview

Huizhisu is a nutraceutical product composed of extracts from rice bran and soybean. It is primarily investigated in China for its potential therapeutic effects in children with autism spectrum disorder (ASD). The product is hypothesized to support neurodevelopment and improve behavioral symptoms associated with ASD, possibly through nutritional support or metabolic modulation provided by its plant-based components. A multicenter, open, self-controlled clinical trial (ChiCTR1900027251) has been conducted by Beijing Anding Hospital to evaluate its efficacy and safety in this population.

Brand names: Huizhisu
Other names: rice bran and soybean extract

Beyond the preview

Go deeper on Huizhisu (Beijing Anding Hospital).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huizhisu (Beijing Anding Hospital).

Explore the full profile